https://www.dukehealth.org/clinical-trials/directory/pro00114755
CytoAgents:CTO1681 (Diffuse Large... | Clinical Trials at Duke
clinical trialsdiffuselargeduke
https://cytoagents.com/
Innovative Treatment for a Pipeline of Inflammatory Indications | CytoAgents
May 18, 2026 - CTO1681: Orally bioavailable, steroid sparing immunomodulatorfor multiple indications driven by cytokine inducing inflammation
treatment forinnovativepipelineinflammatoryindications